Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression

doi:10.3748/wjg.v31.i1.101198

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1225)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-9) series, Tables (1-3) series.

Item

Count

PDF

HTML

701

Figures (1-9)

116

Tables (1-3)

134

Sum=977

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

163

Sum=193

Jan 7, 2025 (publication date) through Feb 27, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jan 7, 2025; 31(1): 101198
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.101198

Full Size Figure Download Figure

Figure 2 Kaplan-Meier survival analysis for all 111 hepatocellular carcinoma patients stratified by high and low ASH1L expression. A: The overall survival of patients with hepatocellular carcinoma; B: Recurrence-free survival is shown for the same cohort of patients.

Citation: Yu XH, Xie Y, Yu J, Zhang KN, Guo ZB, Wang D, Li ZX, Zhang WQ, Tan YY, Zhang L, Jiang WT. Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression. World J Gastroenterol 2025; 31(1): 101198
URL: https://www.wjgnet.com/1007-9327/full/v31/i1/101198.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i1.101198